A5009565865- Pancreatic and Hepatic Oncology Research
- Cancer, Hypoxia, and Metabolism
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- RNA modifications and cancer
- HIV Research and Treatment
- CAR-T cell therapy research
- HIV/AIDS Research and Interventions
- Cancer Immunotherapy and Biomarkers
- Tissue Engineering and Regenerative Medicine
- HIV/AIDS drug development and treatment
- Pancreatic function and diabetes
- Growth Hormone and Insulin-like Growth Factors
- Cancer Cells and Metastasis
- 3D Printing in Biomedical Research
- RNA Interference and Gene Delivery
- Nanoplatforms for cancer theranostics
- Muscle Physiology and Disorders
- Microfluidic and Capillary Electrophoresis Applications
- Mesenchymal stem cell research
- HIV-related health complications and treatments
- Immune cells in cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Protein Tyrosine Phosphatases
- Nanopore and Nanochannel Transport Studies
Houston Methodist
2017-2025
Methodist Hospital
2024
Cornell University
2024
The University of Texas MD Anderson Cancer Center
2012-2016
The University of Texas Health Science Center at San Antonio
2012
Abstract The molecular basis underlying the particularly aggressive nature of pancreatic ductal adenocarcinoma (PDAC) still remains unclear. Here we report evidence that insulin-like growth factor–binding protein IGFBP2 acts as a potent oncogene to drive its extremely malignant character. We found elevated expression in primary tumors was associated with lymph node metastasis and shorter survival patients PDAC. Enforced promoted invasion PDAC cells vitro vivo by inducing NF-κB–dependent...
Abstract Agonist CD40 monoclonal antibodies (mAb) is a promising immunotherapeutic agent for cold‐to‐hot tumor immune microenvironment (TIME) conversion. Pancreatic ductal adenocarcinoma (PDAC) an aggressive and lethal cancer known as desert, therefore urgently needs more effective treatment. Conventional systemic treatment fails to effectively penetrate the characteristic dense stroma. Here, it shown that sustained low‐dose intratumoral delivery of mAb via nanofluidic drug‐eluting seed...
Insulin-like growth factor-binding protein 2 (IGFBP2) is increasingly recognized as a glioma oncogene, emerging target for therapeutic intervention. In this study, we used an integrative approach to characterizing the IGFBP2 network, combining transcriptional profiling of human with validation in glial cells and replication-competent ASLV long terminal repeat splice acceptor/tv-a mouse system. We demonstrated that expression closely linked genes integrin integrin-linked kinase (ILK) pathways...
The fundamental limitations of systemic therapeutic administration have prompted the development local drug delivery platforms as a solution to increase effectiveness and reduce side effects. By confining therapeutics site disease, technologies can enhance index. This review highlights recent advances opportunities in strategies for cancer treatment addition challenges that need be addressed facilitate clinical translation. benefits combined with technological advancements increased...
Pancreatic islet transplantation efficacy for type 1 diabetes (T1D) management is limited by hypoxia-related graft attrition and need systemic immunosuppression. To overcome these challenges, we developed the Neovascularized Implantable Cell Homing Encapsulation (NICHE) device, which integrates direct vascularization facile mass transfer localized immunosuppressant delivery rejection prophylaxis. Here, investigated NICHE allogeneic long-term reversal in an immunocompetent, male rat model. We...
Insulin-like growth factor binding protein 2 (IGFBP2) overexpression is common in high-grade glioma and both a strong biomarker of aggressive behaviour well-documented prognostic factor. IGFBP2 member the secreted IGFBP family that functions by interacting with circulating IGFs to modulate IGF-mediated signalling. This traditional view activities has been challenged recognition diverse cellular locations members family. previously established as driver progression higher grade. In this...
An implantable nanofluidic device for remote controlled drug delivery.
The impact of pre-exposure prophylaxis (PrEP) on slowing the global HIV epidemic hinges effective drugs and delivery platforms. Oral drug regimens are pillar PrEP, but variable adherence has spurred development long-acting systems with aim increasing PrEP access, uptake, persistence. We have developed a subcutaneous nanofluidic implant that can be refilled transcutaneously for sustained release islatravir, nucleoside reverse transcriptase translocation inhibitor is used PrEP. In rhesus...
Pre-exposure prophylaxis (PrEP) using antiretroviral oral drugs is effective at preventing HIV transmission when individuals adhere to the dosing regimen. Tenofovir alafenamide (TAF) a potent drug, with numerous long-acting (LA) delivery systems under development improve PrEP adherence. However, none has undergone preventive efficacy assessment. Here we show that LA TAF novel subcutaneous nanofluidic implant (nTAF) confers partial protection from transmission. We demonstrate sustained...
Cell encapsulation is an attractive transplantation strategy to treat endocrine disorders. Transplanted cells offer a dynamic and stimulus-responsive system that secretes therapeutics based on patient need. Despite significant advancements, challenge in allogeneic cell maintaining sufficient oxygen nutrient exchange, while providing protection from the host immune system. To this end, we developed subcutaneously implantable dual-reservoir integrating situ prevascularization local...
Abstract Cell delivery and encapsulation platforms are under development for the treatment of Type 1 Diabetes among other diseases. For effective cell engraftment, these require establishing an immune‐protected microenvironment as well adequate vascularization oxygen supply to meet metabolic demands therapeutic cells. Current rely on 1) immune isolating barriers indirect or 2) direct with local systemic modulatory molecules. Supported by experimental data, here a broadly applicable...
New treatment strategies are urgently needed for pancreatic ductal adenocarcinoma (PDAC), which is one of the deadliest tumors nowadays. PDAC marked by hypoxia, intrinsic chemoresistance, a "cold" tumor microenvironment, and dense desmoplastic stroma, hinders drug penetration. This study investigates combined effect iron-doped, lipid-coated zinc oxide nanoparticles enhanced with fluorescent sonosensitizer local ultrasound stimulation in treating PDAC. Nanoparticles were synthesized coated...